Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCAI
āļāļ·āđāļāļāļĢāļīāļĐāļąāļCaris Life Sciences Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 18, 2025
āļāļĩāļāļĩāđāļHalbert (David Dean)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJun 18
āļāļĩāđāļāļĒāļđāđ750 W. John Carpenter Freeway
āđāļĄāļ·āļāļIRVING
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ75039
āđāļāļĢāļĻāļąāļāļāđ18667718946
āđāļ§āđāļāđāļāļāđhttps://www.carislifesciences.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCAI
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 18, 2025
āļāļĩāļāļĩāđāļHalbert (David Dean)
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Vice Chairman of the Board
Vice Chairman of the Board
Mr. Luke Power
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Independent Director
Mr. Peter M. Castleman
Lead Independent Director
Lead Independent Director
Mr. Joseph E. Gilliam
Independent Director
Mr. Jon S. Halbert
Director
Ms. Laura I. Johansen
Independent Director
Dr. Lloyd B. Minor, M.D.
Independent Director
Mr. Vijay Mohan
Independent Director
Mr. Danny Phillips
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Vice Chairman of the Board
Vice Chairman of the Board
Mr. Luke Power
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Independent Director
Mr. Peter M. Castleman
Lead Independent Director
Lead Independent Director
Mr. Joseph E. Gilliam
Independent Director
Mr. Jon S. Halbert
Director
ARK Genomic Revolution ETF
Texas Capital Texas Small Cap Equity Index ETF
Franklin Genomic Advancements ETF
Invesco Russell 1000 Equal Weight ETF
T Rowe Price Small-Mid Cap ETF
Texas Capital Texas Equity Index ETF
Fidelity Nasdaq Composite Index ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ARK Genomic Revolution ETF
āļŠāļąāļāļŠāđāļ§āļ0.67%
Texas Capital Texas Small Cap Equity Index ETF
āļŠāļąāļāļŠāđāļ§āļ0.52%
Renaissance IPO ETF
āļŠāļąāļāļŠāđāļ§āļ0.43%
RiverNorth Patriot ETF
āļŠāļąāļāļŠāđāļ§āļ0.3%
Franklin Genomic Advancements ETF
āļŠāļąāļāļŠāđāļ§āļ0.29%
Invesco Russell 1000 Equal Weight ETF
āļŠāļąāļāļŠāđāļ§āļ0.08%
Inspire 500 ETF
āļŠāļąāļāļŠāđāļ§āļ0.07%
T Rowe Price Small-Mid Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.05%
Texas Capital Texas Equity Index ETF
āļŠāļąāļāļŠāđāļ§āļ0.04%
Fidelity Nasdaq Composite Index ETF
āļŠāļąāļāļŠāđāļ§āļ0.02%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ